Business Wire

Xsolla Redefines the Metaverse With New Metasites Platform for Unreal Creators

15.8.2025 18:00:00 CEST | Business Wire | Press Release

Share

Xsolla, a global commerce company helping developers launch, grow and monetize their games, announces today the latest evolution of its Metasite™ platform, designed to meet the growing demand for immersive, accessible, and creator-driven Metaverse experiences. Reimagined for Unreal Engine creators, studios, and digital communities, Xsolla Metasite™ offers a seamless, browser-based experience that enables developers and creators to publish, share, and monetize real-time 3D worlds with built-in multiplayer, voice chat, and monetization tools all without requiring downloads, installations, or backend infrastructure.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250815735499/en/

(Graphic: Xsolla)

Powered by advancements in cloud streaming and WebGL, Xsolla Metasite™ is purpose-built for today’s creators and developers seeking a better way to deploy multiplayer experiences, simplify distribution, and activate their audiences.

Key benefits of the updated Metasites platform include:

  • Frictionless Multiplayer Access: Launch interactive 3D worlds with instant play—no installs or downloads required.
  • Built for Unreal Engine: New plugin support simplifies multiplayer integration, content sharing, and live updates.
  • Creator Monetization: Enable payments for in-game items or access, powered by Xsolla’s secure payment ecosystem.
  • Advanced Referral & Spawn Tools: Empower players to invite others with exact in-game placement and track campaign performance in real time.
  • Massive Multiplayer & Community Features: Support for 10,000+ concurrent users (CCU) powered by Quark, with integrated voice and text chat, custom avatars, and scalable session architecture.

“Early visions of the Metaverse failed because they were inaccessible, fragmented, and hard to scale,” said Chris Hewish, President at Xsolla. “We’re changing that. With Xsolla Metasite™, players don’t need downloads or expensive hardware. They can launch real-time 3D worlds directly in the browser with built-in monetization, multiplayer, and growth tools.”

The global Metaverse market is projected to reach $103 billion in value by 2025, with user numbers forecasted to grow to 2.6 billion by 2030. However, many past platforms fell short due to high entry barriers and poor UX. Xsolla Metasite™ addresses those challenges head-on by focusing on frictionless delivery, freedom for creators and developers, and monetization at scale.

The platform supports game demos, social hubs, digital art galleries, multiplayer showcases, and more. With community-building tools at the core, Metasites supports user-driven content, real-time sharing, and scalable monetization through game keys, currency systems like Blue Orbs, or direct player purchases.

Xsolla invites developers, artists, and creative teams to experience Metasites for themselves. Teams can sign up to launch their interactive site or contact Xsolla to learn about early activation programs and partnership opportunities.

For a complete list of enhancements and developer tools, visit: xsolla.pro/rws25metasites

About Xsolla

Xsolla is a global commerce company with robust tools and services to help developers solve the inherent challenges of the video game industry. From indie to AAA, companies partner with Xsolla to help them fund, distribute, market, and monetize their games. Grounded in the belief in the future of video games, Xsolla is resolute in the mission to bring opportunities together, and continually make new resources available to creators. Headquartered and incorporated in Los Angeles, California, Xsolla operates as the merchant of record and has helped over 1,500+ game developers to reach more players and grow their businesses around the world. With more paths to profits and ways to win, developers have all the things needed to enjoy the game.

For more information, visit xsolla.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250815735499/en/

Contacts

Media Contact

Derrick Stembridge
Vice President of Global Public Relations, Xsolla
d.stembridge@xsolla.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye